Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Apr 9, 2014 (13 years ago)

Pantoprazole Sodium

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Correct Labeled Product Miscart/Mispack: some cartons labeled as Pantoprazole Sodium Delayed-Release may contain correctly labeled blister cards of Lorazepam tablets

Cause type: Labeling / mix-up

Wrong label, wrong strength, mixed-up products, or packaging errors. One of the most dangerous causes - you can end up taking the wrong drug or the wrong dose. All labeling / mix-up recalls.

What was recalled

Pantoprazole Sodium, Delayed-release tablets, USP, 40 mg tablets, 100 (10x10) unit dose packages, Manufactured by Dr. Reddy's Laboratories Limited, India and Distributed by Major Pharmaceuticals, Livonia, MI --- NDC 0904-6235-61

Affected NDC 0904-6235-61

Compare with the code on your package — it is the most precise check available.

Drug: Pantoprazole Category: Heartburn & Stomach Medication

Recalling firm
Legacy Pharmaceutical Packaging
NDC code
0904-6235-61
Origin
MO, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1363-2014 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Pantoprazole recalls

See all
Class II · Moderate risk

Pantoprazole Sodium

Discoloration: Firm received five (5) complaints stating that, "Tablets discolored darker than normal and have lighter-colored spots."

Ongoing Failed specification Hetero Labs Limited (Unit V) NDC 31722-713-10 D-0484-2026
Class II · Moderate risk

Pantoprazole sodium for Injection 40 mg*/vial

CGMP Deviations; The impacted product and lot number was inadvertently placed into saleable inventory, which does not comply with approved procedures.

Completed cGMP deviation Methapharm Inc NDC 67850-150-10 D-0540-2023

Other recalls by Legacy Pharmaceutical Packaging

All 2014 recalls
Class II · Moderate risk

Sertraline Tablets

CGMP Deviations: Inadequate line clearance which may result in a potential comingling of product.

Ongoing cGMP deviation Legacy Pharmaceutical Packaging LLC NDC 68645-523-54 D-0205-2024
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: Detection of trace amounts of N-Methylnitrosobutyric acid (NMBA) impurity found in the Active Pharmaceutical Ingredient (API)

Ongoing Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1263-2019
Class II · Moderate risk

Losartan Potassium Tablets

CGMP Deviations: presence of an impurity, N-Methylnitrosobutyric acid (NMBA) detected.

Terminated Nitrosamine impurity Legacy Pharmaceutical Packaging LLC NDC 68645-494-54 D-1075-2019